| abstract |
The present disclosure relates to methods of using IL-17 antagonists, eg, IL-17 antibodies, such as secukinumab, to treat patients with autoimmune diseases, eg, to treat psoriatic arthritis (PsA) or axonal spine Methods of arthritis (axSpA), eg, non-radiological axonal spondyloarthritis (nr‑axSpA) or ankylosing spondylitis (AS). Also disclosed herein are methods of using an IL-17 antagonist, eg, an IL-17 antibody, such as secukinumab, for inhibiting the progression of structural damage in PsA and axSpA patients. The present disclosure also provides medicaments, pharmaceutical formulations, dosage forms, and kits for use in the methods of the present disclosure. |